ArticleAdvanced healthcare materials2026
Matrix Stiffness Directs Stemness Signatures in Breast Cancer.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Phenotypic plasticity contributes to tumor progression and metastasis, with the tumor microenvironment playing a central role through dynamic cues such as extracellular matrix stiffness. In this study, 2D and 3D in vitro breast cancer models were developed to investigate how ECM mechanics regulate cancer cell behavior. Hydrogel micropatterning enabled the mimicry of spatial confinement and stiffness in 2D microtumors, while drop-on-demand bioprinting facilitated the fabrication of mechanically tuneable 3D matrices. Phenotypic characterisation was conducted using immunofluorescence staining for molecular markers of plasticity and stemness, and drug resistance was assessed with doxorubicin and enzalutamide, the latter chosen for its emerging relevance in targeting stem-like cancer cell populations. Soft matrices promoted stem-like phenotypes, elevated ALDH1 expression, and enhanced drug resistance, whereas stiff matrices maintained a more differentiated profile. CD44 isoform expression was stiffness-dependent, with the CD44 standard isoform enriched in soft matrices and the CD44 variant 9 isoform enriched in stiff matrices. The 3D matrices reproduced the mechanical regulation observed in 2D, providing a physiologically relevant platform for high-throughput investigation of biomechanics-driven cancer progression. These findings highlight the role of matrix stiffness in driving breast cancer phenotypic heterogeneity and support the application of microengineered synthetic matrices for studying metastasis and drug resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.